Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
about
Diverse mechanisms of antiepileptic drugs in the development pipelineRole of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Pharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepineEslicarbazepine acetate (BIA 2-093).Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application.New antiepileptic drugs that are second generation to existing antiepileptic drugs.Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.Eslicarbazepine acetate for the treatment of partial epilepsy.Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects.Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’.Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc StudyEslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures
P2860
Q24675330-F3B30DB9-74F2-407C-B30E-55150CB2D921Q33802172-08AF2D9E-79AA-4203-92CF-51F2C81A1440Q33949491-709E8F9F-FE70-47DE-AE95-688C224274A5Q34276263-4D694731-B19D-4C2E-88D9-B0D8630E70CEQ34329823-58C74DE4-E374-45FC-A0C5-74BBB64FA8C9Q34596785-0AB907F3-EAA6-477D-84A1-2E359484B7EEQ34941977-448CDC8F-D645-44DE-B130-45579FCA2806Q36491829-FE4B0528-2401-4B48-B74E-F73AEF076768Q36947574-D8967B84-F9F0-482D-8A48-D7E8483922F2Q37694387-6674CE21-933F-4DE4-9658-C92A4F12DF5FQ37950518-E6EF72F2-95B2-44DC-AC48-BA25D182382CQ37957121-4679E8AA-1425-430C-A2FF-924503ECC5DCQ37992162-AFA400CE-4F5C-4175-BDDF-282841085497Q38223958-3FF3C5D2-59CF-48FE-A388-FF3B0B5BE462Q38542064-538D61CF-F6C8-4257-8C30-A77184A49C69Q38800995-0035E239-FCA6-4CB4-B187-A3AA9F2C3741Q38826584-FC51B2CA-7735-4C30-99D8-990BD504DD79Q38974450-DCE92967-C74B-4AFD-B44D-DCEFFD23AC87Q44062629-0F2E3DCA-C5C5-4BFB-A482-8C0A99AFBB01Q46265751-0A968D57-1565-45A9-82B3-65316E68A8F2Q46650441-946B6B2C-D7A7-4C09-A831-9344AF2BF466Q55221688-31AE05D0-CC26-4F31-BD87-98DFD306A5D9Q59284818-C7AEE42D-52F4-46A2-B5B1-AEDE52F3D81EQ59284846-C40A6B76-77EA-4958-A198-ED5CE4F1D241
P2860
Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Safety, tolerability, and phar ...... study in young healthy humans.
@en
Safety, tolerability, and phar ...... study in young healthy humans.
@nl
type
label
Safety, tolerability, and phar ...... study in young healthy humans.
@en
Safety, tolerability, and phar ...... study in young healthy humans.
@nl
prefLabel
Safety, tolerability, and phar ...... study in young healthy humans.
@en
Safety, tolerability, and phar ...... study in young healthy humans.
@nl
P2860
P356
P1476
Safety, tolerability, and phar ...... study in young healthy humans.
@en
P2860
P304
P356
10.1177/0091270004267591
P577
2004-08-01T00:00:00Z